BPC 157 10mg
10mg
Investigated in preclinical studies for its potential role in tissue regeneration, gastrointestinal mucosal repair, and modulation of inflammatory pathways.
For research use only
TB500 10mg
10mg
Synthetic analogue of Thymosin Beta-4 studied in preclinical models for its potential involvement in wound healing mechanisms, skeletal muscle repair, and the downregulation of pro-inflammatory cytokines.
For research use only
GHK-CU 50mg
50mg
Naturally occurring copper-binding tripeptide investigated in preclinical research for its potential role in extracellular matrix remodeling, collagen and elastin synthesis, and cutaneous tissue regeneration.
For research use only
GHK-CU 100mg
100mg
Naturally occurring copper-binding tripeptide investigated in preclinical research for its potential role in extracellular matrix remodeling, collagen and elastin synthesis, and cutaneous tissue regeneration.
For research use only
TESAMORELIN 10mg
10mg
Synthetic analogue of growth hormone-releasing hormone (GHRH) studied in research settings for its potential role in growth hormone secretion pathways and the modulation of visceral adipose tissue metabolism.
For research use only
MOTS-C 10mg
10mg
Mitochondria-derived peptide investigated in preclinical studies for its potential role in mitochondrial energy regulation, metabolic homeostasis, and insulin signaling pathways.
For research use only
MOTS-C 20mg
20mg
Mitochondria-derived peptide investigated in preclinical studies for its potential role in mitochondrial energy regulation, metabolic homeostasis, and insulin signaling pathways.
For research use only
RETATRUTIDE 10mg
10mg
Triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, investigated in research settings for its potential role in energy expenditure regulation, adipose tissue reduction, and metabolic pathway modulation.
For research use only
RETATRUTIDE 15mg
15mg
Triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, investigated in research settings for its potential role in energy expenditure regulation, adipose tissue reduction, and metabolic pathway modulation.
For research use only
RETATRUTIDE 20mg
20mg
Triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, investigated in research settings for its potential role in energy expenditure regulation, adipose tissue reduction, and metabolic pathway modulation.
For research use only
CJC1295 NO DAC+IPA 10mg
10mg
Commonly investigated together in preclinical research for their potential synergistic role in pulsatile growth hormone release and somatotropic axis modulation.
For research use only
GLOW 70mg (50+10+10)
70mg
Proprietary research blend combining BPC-157, TB-500, and GHK-Cu, investigated in preclinical settings for their potential synergistic role in extracellular matrix remodeling, collagen biosynthesis, tissue regeneration, and oxidative stress modulation in cutaneous tissue.
For research use only
BPC 157 10mg
10mg
Investigated in preclinical studies for its potential role in tissue regeneration, gastrointestinal mucosal repair, and modulation of inflammatory pathways.
For research use only
RETATRUTIDE 15mg
15mg
Triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, investigated in research settings for its potential role in energy expenditure regulation, adipose tissue reduction, and metabolic pathway modulation.
For research use only
SEMAX 22,5mg
22,5mg
Investigated in preclinical research for its potential role in cognitive function modulation, neurotrophic factor expression, and neuroprotective mechanisms.
For research use only
NAD+ 300mg
300mg
Studied in preclinical research for its potential role in cellular energy metabolism, mitochondrial function, and DNA repair pathway modulation.
For research use only
BACTERIOSTATIC WATER 10mL
10mL
For research use only